Imaging With [89Zr]Zr-DFO-SC16.56 Anti-DLL3 Antibody in High-Grade Neuroendocrine Tumours of Lung and Prostate
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
Lancet Oncol 2024 Jun 28;[EPub Ahead of Print], S Tendler, MP Dunphy, M Agee, J O'Donoghue, RG Aly, NJ Choudhury, A Kesner, A Kirov, A Mauguen, MK Baine, H Schoder, WA Weber, N Rekhtman, SK Lyashchenko, L Bodei, MJ Morris, JS Lewis, CM Rudin, JT PoirierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.